From February 24 to 26, a total of 200 stakeholders in CNS drug development came together at Hotel Jakarta in Amsterdam. During the three-day program, they exchanged knowledge on the latest developments in CNS drug discovery, including novel treatment modalities such as gene therapies and RNA therapeutics, as well as financial and business aspects of the field. Most importantly, there was plenty of time for networking.

The team of business developers from Amsterdam Neuroscience was present to connect (inter)national biotech companies with researchers within the Amsterdam Neuroscience community.

Pieter van Bokhoven, Chief Scientific Officer at Amsterdam Neuroscience & IXA Neuroscience: “Having all these experts in CNS drug discovery visit us here in Amsterdam every February is an absolute honour and guarantees the most enjoyable week of the year.”

About BIO Neuroscience

BIO-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector. It is the event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs, and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development. Bio-Neuroscience is organized by Broadreach Global and Amsterdam Neuroscience.

More information